BACKGROUND AND AIMS: Methadone patients who discontinue treatment are at high risk of relapse, yet a substantial proportion discontinue treatment within the first year. We investigated whether a patient-centered approach to methadone treatment improved participant outcomes at 12 months following admission, compared with methadone treatment-as-usual. DESIGN: Two-arm open-label randomized trial. SETTING: Two methadone treatment programs (MTPs) in Baltimore, MD, USA. PARTICIPANTS: Three hundred newly admitted MTP patients were enrolled between 13 September 2011 and 26 March 2014. Their mean age was 42.7 years [standard deviation (SD) = 10.1] and 59% were males. INTERVENTION: Newly admitted MTP patients were assigned randomly to either patient-centered methadone treatment (PCM; n = 149), which modified the MTP's rules (e.g. counseling attendance was optional), and counselor roles (e.g. counselors were not responsible for enforcing clinic rules) or treatment-as-usual (TAU; n = 151). MEASUREMENTS: The primary outcome was opioid-positive urine test at 12-month follow-up. Other 12-month outcomes included days of heroin and cocaine use, cocaine-positive urine tests, meeting DSM-IV opioid and cocaine dependence diagnostic criteria, HIV risk behavior and quality of life and retention in treatment. FINDINGS: There was no significant difference between PCM and TAU conditions in opioid-positive urine screens at 12 months [adjusted odds ratio = 0.98; 95% confidence interval (CI) = 0.61, 1.56]. There were also no significant differences in any of the secondary outcome measures (all Ps > 0.05) except Quality of Life Global Score (P = 0.04; 95% CI = 0.01, 0.45). There were no significant differences between conditions in the number of individual or group counseling sessions attended. (Ps > 0.05). CONCLUSIONS: Patient-centered methadone treatment (with optional counseling and the counselor not serving as the treatment program disciplinarian) does not appear to be more effective than methadone treatment-as-usual.
RCT Entities:
BACKGROUND AND AIMS: Methadonepatients who discontinue treatment are at high risk of relapse, yet a substantial proportion discontinue treatment within the first year. We investigated whether a patient-centered approach to methadone treatment improved participant outcomes at 12 months following admission, compared with methadone treatment-as-usual. DESIGN: Two-arm open-label randomized trial. SETTING: Two methadone treatment programs (MTPs) in Baltimore, MD, USA. PARTICIPANTS: Three hundred newly admitted MTPpatients were enrolled between 13 September 2011 and 26 March 2014. Their mean age was 42.7 years [standard deviation (SD) = 10.1] and 59% were males. INTERVENTION: Newly admitted MTPpatients were assigned randomly to either patient-centered methadone treatment (PCM; n = 149), which modified the MTP's rules (e.g. counseling attendance was optional), and counselor roles (e.g. counselors were not responsible for enforcing clinic rules) or treatment-as-usual (TAU; n = 151). MEASUREMENTS: The primary outcome was opioid-positive urine test at 12-month follow-up. Other 12-month outcomes included days of heroin and cocaine use, cocaine-positive urine tests, meeting DSM-IV opioid and cocaine dependence diagnostic criteria, HIV risk behavior and quality of life and retention in treatment. FINDINGS: There was no significant difference between PCM and TAU conditions in opioid-positive urine screens at 12 months [adjusted odds ratio = 0.98; 95% confidence interval (CI) = 0.61, 1.56]. There were also no significant differences in any of the secondary outcome measures (all Ps > 0.05) except Quality of Life Global Score (P = 0.04; 95% CI = 0.01, 0.45). There were no significant differences between conditions in the number of individual or group counseling sessions attended. (Ps > 0.05). CONCLUSIONS:Patient-centered methadone treatment (with optional counseling and the counselor not serving as the treatment program disciplinarian) does not appear to be more effective than methadone treatment-as-usual.
Authors: Matthias Vonmoos; Lea M Hulka; Katrin H Preller; Daniela Jenni; Claudia Schulz; Markus R Baumgartner; Boris B Quednow Journal: Drug Alcohol Depend Date: 2013-06-24 Impact factor: 4.492
Authors: Heather Schacht Reisinger; Robert P Schwartz; Shannon Gwin Mitchell; James A Peterson; Sharon M Kelly; Kevin E O'Grady; Erica A Marrari; Barry S Brown; Michael H Agar Journal: J Psychoactive Drugs Date: 2009-09
Authors: Sharon M Kelly; Kevin E O'Grady; Barry S Brown; Shannon Gwin Mitchell; Robert P Schwartz Journal: Am J Drug Alcohol Abuse Date: 2010-05 Impact factor: 3.829
Authors: Stacey C Sigmon; Andrew C Meyer; Bryce Hruska; Taylor Ochalek; Gail Rose; Gary J Badger; John R Brooklyn; Sarah H Heil; Stephen T Higgins; Brent A Moore; Robert P Schwartz Journal: Addict Behav Date: 2015-07-29 Impact factor: 3.913
Authors: Shannon Gwin Mitchell; Sharon M Kelly; Barry S Brown; Heather Schacht Reisinger; James A Peterson; Adrienne Ruhf; Michael H Agar; Robert P Schwartz Journal: J Psychoactive Drugs Date: 2009-06
Authors: Dharushana Muthulingam; Joshua Bia; Lynn M Madden; Scott O Farnum; Declan T Barry; Frederick L Altice Journal: J Subst Abuse Treat Date: 2019-01-26
Authors: Shannon Gwin Mitchell; Laura B Monico; Elizabeth Lertch; Sharon M Kelly; Jan Gryczynski; Jerome H Jaffe; Kevin E O'Grady; Robert P Schwartz Journal: J Behav Health Serv Res Date: 2018-07 Impact factor: 1.505
Authors: Robert P Schwartz; Sharon M Kelly; Shannon Gwinn Mitchell; Jan Gryczynski; Kevin E O'Grady; Jerome H Jaffe Journal: Drug Alcohol Depend Date: 2017-09-14 Impact factor: 4.492
Authors: Lindsay M S Oberleitner; Lynn M Madden; Dharushana Muthulingam; Ruthanne Marcus; David E Oberleitner; Mark Beitel; Marina Gaeta; Joseph F Tamberelli; Declan T Barry Journal: J Subst Abuse Treat Date: 2020-11-02
Authors: Mary A Hatch-Maillette; K Michelle Peavy; Judith I Tsui; Caleb J Banta-Green; Stephen Woolworth; Paul Grekin Journal: J Subst Abuse Treat Date: 2020-12-05
Authors: Jan Klimas; Christopher Fairgrieve; Helen Tobin; Catherine-Anne Field; Clodagh Sm O'Gorman; Liam G Glynn; Eamon Keenan; Jean Saunders; Gerard Bury; Colum Dunne; Walter Cullen Journal: Cochrane Database Syst Rev Date: 2018-12-05
Authors: E Jennifer Edelman; Geliang Gan; James Dziura; Denise Esserman; Kenneth L Morford; Elizabeth Porter; Philip A Chan; Deborah H Cornman; Benjamin J Oldfield; Jessica E Yager; Srinivas B Muvvala; David A Fiellin Journal: J Acquir Immune Defic Syndr Date: 2021-07-01 Impact factor: 3.771